Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -420.0%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $20M | $60M | $123M | $83M | $43M | $27M | $29M | $21M |
| Enterprise Value | $-11773037 | $6M | $47M | $99M | $64M | $13M | $18M | $33M | $21M |
| P/E Ratio → | -0.12 | — | — | — | — | — | — | — | 35.74 |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.28 | 2.34 | 73.84 | 21.43 | 9.88 | 1.49 | 4.90 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -420.0% | -420.0% | -916.2% | -556.4% | -131.3% | -49.9% | -69.2% | — | — |
| ROA | -126.4% | -126.4% | -152.6% | -184.2% | -96.7% | -42.4% | -86.3% | -2.6% | -2.6% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -423.1% | -423.1% | -829.4% | -510.2% | -127.9% | -55.4% | -66.4% | -1.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.56 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.62 | -16.02 | -4.09 | -2.21 | -1.03 | -1.60 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1479.82 | -1479.82 | -1615.44 | -1163.64 | -132.97 | -4185.80 | -1.68 | -0.80 | -2.01 |
Net cash position: cash ($14M) exceeds total debt ($406875)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.08 | 2.08 | 1.01 | 1.38 | 1.90 | 13.39 | 6.57 | 0.00 | — |
| Quick Ratio | 2.08 | 2.08 | 1.01 | 1.38 | 1.90 | 13.39 | 6.57 | 0.00 | — |
| Cash Ratio | 1.98 | 1.98 | 0.92 | 1.36 | 1.86 | 12.66 | 6.57 | 0.00 | — |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 2.8% |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $4M | $2M | $1M | $975824 | $739542 | $153084 | $138531 | $101984 |
Clinical trial funding shortfall
Based on reported figures, RVPH trades at a price-to-book ratio of 0.28, which suggests a significant valuation discount compared to commercial-stage peers like ACAD, likely reflecting the market's skepticism regarding the company's ability to successfully navigate the remaining regulatory hurdles for its lead clinical asset.
The low P/B ratio indicates that the market is heavily discounting the company's book value, which is primarily composed of cash rather than tangible operating assets. This valuation gap appears to be a structural response to the binary risk inherent in a single-asset biotech firm that lacks the diversified revenue streams of its larger, commercial-stage competitors.
According to recent financial statements, the current ratio reached 3.85 in 2026Q1, yet this figure remains misleading as it follows a period of severe liquidity stress where the ratio dipped as low as 0.39 in 2024Q3, indicating a persistent and dangerous reliance on external capital markets.
The extreme fluctuation in the current ratio highlights the company's vulnerability to the timing of equity raises rather than operational cash generation. Investors should monitor the sustainability of this liquidity buffer, as the current cash position appears insufficient to support the long-term requirements of the RECOVER-2 clinical program without further dilution.
As reported in financial filings, the company maintains a negligible debt-to-equity ratio of 0.01% as of 2026Q1, which suggests that management has avoided traditional debt financing in favor of equity issuance to fund its ongoing research and development activities during this pre-revenue phase.
While the lack of debt minimizes interest coverage risk, it underscores the company's total reliance on equity markets to sustain operations. This capital structure strategy may protect the firm from insolvency in the short term, but it places the entire burden of financing on existing shareholders through continuous dilution.
Based on the provided financial data, analysts frequently misapply net margin and P/E ratios to RVPH, which obscures the reality that these metrics are essentially meaningless for a pre-revenue clinical-stage firm that is currently expensing all its primary investments in intellectual property.
Using traditional profitability ratios for a company in this stage of development fails to account for the fact that R&D spending is a capital investment rather than an operational inefficiency. A more appropriate analytical framework would focus on the cash burn rate relative to the clinical trial timeline and the probability-weighted net present value of the lead asset.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RVPH stock.
Reviva Pharmaceuticals Holdings, Inc.'s current P/E ratio is -0.1x. The historical average is 35.7x.
Reviva Pharmaceuticals Holdings, Inc.'s return on equity (ROE) is -420.0%. The historical average is -167.6%.
Based on historical data, Reviva Pharmaceuticals Holdings, Inc. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.